Su Leonard T, Gopal Kapil, Wang Zhonglin, Yin Xiaoqing, Nelson Anthony, Kozyak Benjamin W, Burkman James M, Mitchell Marilyn A, Low David W, Bridges Charles R, Stedman Hansell H
Department of Surgery, University of Pennsylvania, Philadelphia, PA 19104, USA.
Circulation. 2005 Sep 20;112(12):1780-8. doi: 10.1161/CIRCULATIONAHA.105.534008. Epub 2005 Sep 12.
The muscular dystrophies exemplify a class of systemic disorders for which widespread protein replacement in situ is essential for treatment of the underlying genetic disorder. Somatic gene therapy will require efficient, scale-independent transport of DNA-containing macromolecular complexes too large to cross the continuous endothelia under physiological conditions. Previous studies in large-animal models have revealed a trade-off between the efficiency of gene transfer and the inherent safety of the required surgical and pharmacological interventions to achieve this.
Rats and dogs underwent limb or hemibody isolation via atraumatic tourniquet placement or myocardial isolation via heterotopic transplantation. Recombinant adenovirus (10(13) particles per kilogram) or recombinant adeno-associated virus (10(14) genome copies/kg) encoding the lacZ transgene was delivered through pressurized venous infusion without pharmacological mediators. Muscle exhibited almost 100% myofiber transduction in rats and dogs by X-galactosidase staining and significantly higher beta-galactosidase levels compared with nonpressurized delivery. No significant difference was seen in beta-galactosidase levels between 100- or 400-mm Hg groups. The <50-mm Hg group yielded inhomogeneous and significantly lower transgene expression.
Uniform scale- and vector-independent skeletal and cardiac myofiber transduction is facilitated by pressurized venous infusion in anatomic domains isolated from the central circulation without pharmacological interference with cardiovascular homeostasis. We provide the first demonstration of uniform gene transfer to muscle fibers of an entire extremity in the dog, providing a firm foundation for further translational studies of efficacy in canine models for human diseases.
肌肉萎缩症是一类全身性疾病,对于这类疾病,在原位广泛进行蛋白质替代对于治疗潜在的遗传疾病至关重要。体细胞基因治疗需要高效、与规模无关地运输含DNA的大分子复合物,这些复合物太大,在生理条件下无法穿过连续的内皮细胞。此前在大型动物模型中的研究表明,在实现基因转移效率与所需手术和药物干预的固有安全性之间存在权衡。
通过无创止血带放置对大鼠和犬进行肢体或半身隔离,或通过异位移植进行心肌隔离。编码β-半乳糖苷酶转基因的重组腺病毒(每千克10¹³个颗粒)或重组腺相关病毒(每千克10¹⁴个基因组拷贝)通过加压静脉输注给药,无需药物介导。通过X-半乳糖苷酶染色,大鼠和犬的肌肉显示出近100%的肌纤维转导,与非加压给药相比,β-半乳糖苷酶水平显著更高。100或400毫米汞柱组之间的β-半乳糖苷酶水平未见显著差异。<50毫米汞柱组产生的转基因表达不均匀且显著较低。
在与体循环隔离的解剖区域中,通过加压静脉输注可促进骨骼和心肌纤维的均匀、与规模和载体无关的转导,而不会对心血管稳态产生药物干扰。我们首次证明了在犬的整个肢体的肌纤维中实现了均匀的基因转移,为在犬类模型中进一步开展人类疾病疗效的转化研究奠定了坚实基础。